Research Topics
| Sherwyn L SchwartzSummaryAffiliation: Diabetes and Glandular Disease Research Associates Country: USA Publications
| Collaborators
|
Detail Information
Publications
A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitusSherwyn Schwartz
Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
Clin Ther 28:1649-57. 2006..Furthermore, greater amounts of rapid-acting insulin contained within the mixture were associated with better PPG control...
Correct use of a new reusable insulin injection pen by patients with diabetes: a design validation studySherwyn Schwartz
Diabetes and Glandular Disease Research Associates, San Antonio, Texas 78229, USA
J Diabetes Sci Technol 4:1229-35. 2010..The objective of this study was to demonstrate that individuals with diabetes could use the ClikSTAR pen correctly...
Saxagliptin for the treatment of type 2 diabetes mellitus: focus on recent studiesSherwyn L Schwartz
Diabetes and Glandular Disease Clinic, 5107 Medical Drive, San Antonio, TX 78229, USA
Ann Med 44:157-69. 2012..On the basis of this clinical profile, saxagliptin is an attractive option for initial and add-on therapy for T2DM patients with inadequate glycemic control...- A multicenter, open-label, randomized, two-period crossover trial comparing glycemic control, satisfaction, and preference achieved with a 31 gauge x 6 mm needle versus a 29 gauge x 12.7 mm needle in obese patients with diabetes mellitusSherwyn Schwartz
Diabetes and Glandular Disease Research Associates, 5107 Medical Drive, San Antonio, TX 78229, USA
Clin Ther 26:1663-78. 2004..Optimal needle length for subcutaneous insulin injection may differ for obese and nonobese patients, which could affect management of diabetes mellitus (DM)... - Validation of the SoloSTAR insulin penSherwyn Schwartz
Diabetes and Glandular Disease Research Associates, San Antonio, Texas 78229 4801, USA
Diabetes Technol Ther 10:351-7. 2008..This study was designed to validate the use of SoloSTAR (sanofi-aventis Deutschland GmbH, Frankfurt, Germany), a new disposable pen developed for use with insulin glargine by patients with type 1 or type 2 diabetes... - The effect of colesevelam hydrochloride on insulin sensitivity and secretion in patients with type 2 diabetes: a pilot studySherwyn L Schwartz
Diabetes and Glandular Disease Clinic of San Antonio, San Antonio, Texas 78229, USA
Metab Syndr Relat Disord 8:179-88. 2010..This study evaluated the effect of colesevelam hydrochloride on insulin sensitivity, potential binding to glucose, and chronic effect(s) on fasting and postprandial glucose and insulin in patients with type 2 diabetes mellitus... - Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trialSherwyn Schwartz
Cetero Research, San Antonio, TX 78229, USA
Curr Med Res Opin 27:151-62. 2011..This phase III, randomized-withdrawal, placebo-controlled trial evaluated the safety and efficacy of tapentadol extended release (ER) for relieving painful DPN... - Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitusSherwyn L Schwartz
Cetero Research, 5107 Medical Drive, San Antonio, TX 78229, USA
Diabetes Technol Ther 13:1219-27. 2011..Inhibition of SGLT2 represents an innovative approach for plasma glucose control in type 2 diabetes mellitus (T2DM) by blocking glucose reabsorption and enhancing glucose loss in the urine... - Humalog(®) KwikPen™: an insulin-injecting pen designed for ease of useSherwyn L Schwartz
DGD Research, 5107 Medical Drive, San Antonio, TX 78229, USA
Expert Rev Med Devices 7:735-43. 2010..Together with an engineering study demonstrating smoother injections and reduced dosing error versus a comparator pen, recent evidence demonstrates the Humalog KwikPen device is an accurate, easy-to-use, patient-preferred insulin pen... - Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week studySherwyn L Schwartz
Diabetes and Glandular Disease Research Center, San Antonio, Texas, USA
Clin Ther 30:858-67. 2008..The aim of this study was to examine the glucose-lowering effect of exenatide over 24 hours in patients with type 2 diabetes with inadequate glycemic control using metformin, with or without a thiazolidinedione (TZD)... - Safety profile and metabolic effects of 14 days of treatment with DIO-902: results of a phase IIa multicenter, randomized, double-blind, placebo-controlled, parallel-group trial in patients with type 2 diabetes mellitusSherwyn L Schwartz
Diabetes and Glandular Disease Clinic, San Antonio, Texas, USA
Clin Ther 30:1081-8. 2008..Elevated levels of cortisol have been implicated in the development of type 2 diabetes mellitus and the metabolic syndrome. Modulation of cortisol levels and activity may be useful in the treatment of type 2 diabetes and its comorbidities... - Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of two oral drugs: efficacy, safety, and cost analysisSherwyn Schwartz
Diabetes and Glandular Disease Clinic, San Antonio, Texas 78229, USA
Diabetes Care 26:2238-43. 2003..0%) were randomly assigned to treatment with either a third oral medication or an insulin 70/30 mix b.i.d. plus metformin for a comparison of efficacy, safety, and cost... - Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetesSherwyn Schwartz
Diabetes and Glandular Disease Research Associates, San Antonio, Texas, USA
Diabetes Care 29:759-64. 2006..CONCLUSIONS: Once- or twice-daily extended-release metformin was as safe and effective as twice-daily immediate-release metformin and provided continued glycemic control for up to 24 weeks of treatment... - The impact of insulin glargine on clinical and humanistic outcomes in patients uncontrolled on other insulin and oral agents: an office-based naturalistic studyJerome S Fischer
Diabetes and Glandular Disease Clinic, San Antonio, TX 78229, USA
Curr Med Res Opin 20:1703-10. 2004..The objective of this study was to evaluate the effectiveness of insulin glargine over a 12-month period in a clinical practice setting, and measure its effects on HRQOL in a subset of patients... - Preference and resource utilization in elderly patients: InnoLet versus vial/syringeJohn Shelmet
Diabetes and Glandular Disease Clinic, 5107 Medical Drive, San Antonio, TX 78229, USA
Diabetes Res Clin Pract 63:27-35. 2004..001). A majority of patients (82%) indicated a preference for the InnoLet device (P<0.001)... - Diabetes and dyslipidaemiaSherwyn L Schwartz
Diabetes and Glandular Disease Clinic, San Antonio, TX 78229-4801, USA
Diabetes Obes Metab 8:355-64. 2006..3 mmol/l). Many diabetic patients may need oral hypoglycaemic agents or insulin to achieve adequate glycaemic control. Intensive insulin therapy can provide tight glycaemic control and reduce elevated triglyceride levels... - Metformin extended release for the treatment of type 2 diabetes mellitusSherwyn L Schwartz
Diabetes and Glandular Disease Clinic, San Antonio, TX 78229, USA
Expert Opin Pharmacother 7:803-9. 2006..Metformin ER was well tolerated at doses of 1500 or 2000 mg/day, with no increase in the frequency or severity of adverse events at the higher dose... - Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing studyChristian Weyer
Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
Diabetes Care 26:3074-9. 2003.... - Improvement in glycemic excursions with a transcutaneous, real-time continuous glucose sensor: a randomized controlled trialSatish Garg
Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, 1775 N Ursula St, A140, Aurora, Colorado 80010, USA
Diabetes Care 29:44-50. 2006..In this study we evaluated the accuracy, safety, and clinical effectiveness of a continuous glucose-sensing device... - Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing studyDavid G Maggs
Amylin Pharmaceuticals, Inc, San Diego, California 92121, USA
Diabetes Metab Res Rev 20:55-60. 2004..To assess the postprandial glucose-lowering effect of the human amylin analog pramlintide when given with insulin lispro in subjects with type 2 diabetes, with an emphasis on the optimal dose timing relative to meals... - Improved glucose excursions using an implantable real-time continuous glucose sensor in adults with type 1 diabetesSatish K Garg
Department of Medicine and Pediatrics, Barbara Davis Center for Childhood Diabetes, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
Diabetes Care 27:734-8. 2004..The capability of emerging glucose sensor technology to continuously monitor glucose levels may provide ways to achieve glycemic targets while reducing hypoglycemia... - Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring systemBruce Bode
Atlanta Diabetes Associates, Atlanta, Georgia, USA
Diabetes Technol Ther 6:105-13. 2004.... - Glycemic characteristics in continuously monitored patients with type 1 and type 2 diabetes: normative valuesBruce W Bode
Atlanta Diabetes Associates, Georgia, USA
Diabetes Care 28:2361-6. 2005.... - Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetesBerrin Ergun-Longmire
Division of Pediatric Endocrinology, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
Ann N Y Acad Sci 1029:260-77. 2004..If confirmed, these findings suggest that diabetic patients over age 20 years with ICA evidence of late-onset immune-mediated diabetes should be considered for oral insulin at 1 mg/day to better retain endogenous insulin secretion... - Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III studyAndrew Lewin
National Research Institute, Los Angeles, CA, USA
Clin Ther 29:844-55. 2007..Combination treatment with metformin and sulfonylurea in patients who failed monotherapy has been reported to be effective in maintaining glycemic control... - Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitusYan ling He
Novartis Institutes for BioMedical Research, Inc, Cambridge, Massachusetts 02139 3584, USA
Clin Pharmacokinet 46:577-88. 2007..Vildagliptin is a dipeptidyl peptidase IV (DPP-4) inhibitor currently under development for the treatment of type 2 diabetes mellitus... - Effects of sulodexide in patients with type 2 diabetes and persistent albuminuriaHiddo Lambers Heerspink
Department of Clinical Pharmacology University Medical Center Groningen, University of Groningen, A Deusinglaan, 19713 AV Groningen, The Netherlands
Nephrol Dial Transplant 23:1946-54. 2008..We have conducted a multi-center randomized double-blind pilot study in order to determine the effect of 6 months' therapy with sulodexide on urinary albumin excretion and to address logistical issues for a full-scale trial... - A continuous glucose sensor based on wired enzyme technology -- results from a 3-day trial in patients with type 1 diabetesBen Feldman
TheraSense, Inc, Alameda, California 94502, USA
Diabetes Technol Ther 5:769-79. 2003..Choice of the site of the implanted sensor (upper arm vs. abdomen) or the capillary blood calibration site (arm vs. finger) did not affect system accuracy...